PROTAC BET Degrader-14
PROTAC BET Degrader-14 is a highly efficient PROTAC targeting BET (bromodomain and extra-terminal domain) . PROTAC BET Degrader-14 can degrade all BET (BRD2, BRD3, BRD4) family proteins. PROTAC BET Degrader-14 potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC50 = 130 nM) and KYSE180 esophageal squamous cell carcinoma cell lines (DC50 = 40 nM) . PROTAC BET Degrader-14’s dependence on the ubiquitin-proteasome system. PROTAC BET Degrader-14 decreases levels of BET-regulated gene products c-Myc, RUNX2, and KRT14. PROTAC BET Degrader-14 can be used for the study of osteosarcoma[1].
Product Specifications
UNSPSC
12352005
Target
C-Myc; Epigenetic Reader Domain; PROTACs
Related Pathways
Apoptosis; Epigenetics; PROTAC
Field of Research
Cancer
Smiles
O=C(C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C(C(C)=C(C)S3)=C3N4C1=NN=C4C)NCCOCCOCCOCCOCCOCCOCCOCCOCC5=CN(N=N5)C(C=C6)=CC7=C6C(NCCCNCC8=CC=C9C(C=CN9)=C8)=CC=N7
Molecular Formula
C59H73ClN12O9S
Molecular Weight
1161.80
References & Citations
[1]Jacobsen IE, et al. Design of tissue-selective PROTACs through recruiting E3 ligase scaffolding protein MAGEA11. bioRxiv [Preprint]. 2025 Nov 3.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD2; BRD3; BRD4
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MEF2C (S387) (Myocyte-specific Enhancer Factor 2C) (Biotin) discontinued
LYZL1, CT (LYZL1, LYC2, Lysozyme-like protein 1) (MaxLight 490)
LYZL1, CT (LYZL1, LYC2, Lysozyme-like protein 1) (MaxLight 490)
